PRESS RELEASES

Made in Italy: ‘beIT’ campaign to promote Italy at 360° kicks off

ROME, Nov. 30, 2021 (GLOBE NEWSWIRE) — (LaPresse) – An extraordinary communication campaign to promote Made in Italy, entitled ‘Italy is simply extraordinary: beIT’, has been successfully launched. The campaign, launched by the Italian Ministry of Foreign Affairs and International Cooperation in collaboration with the Italian Trade Agency (ICE), will have a global dimension with […]

PRESS RELEASES

Degreed named as a Core Challenger in the 2021 Fosway 9-Grid™ for Talent & People Success

The new position reflects Degreed’s continued investment in its product features, market potential, and leadership strength PLEASANTON, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) — Degreed, the workforce upskilling platform, has been named as a Core Challenger in the Fosway 2021 9-Grid™ for Talent & People Success. The new positioning, up from Potential Challenger in 2020, […]

PRESS RELEASES

nCino’s Commercial Banking Solution Ranked “Best-in-Class” by Aite Group for Third Consecutive Time

Customer feedback and product innovation drive nCino as a top technology vendor in the 2021 Impact Matrix WILMINGTON, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, is proud to be named a Best-In-Class vendor by Aite Group […]

PRESS RELEASES

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment […]

PRESS RELEASES

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board […]